JASON ROBERT WESTIN to Prognosis
This is a "connection" page, showing publications JASON ROBERT WESTIN has written about Prognosis.
Connection Strength
0.353
-
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole? Leuk Lymphoma. 2022 05; 63(5):1034-1044.
Score: 0.058
-
Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep. 2009 Oct; 4(4):218-24.
Score: 0.025
-
Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44.
Score: 0.015
-
Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 10; 62(10):2400-2407.
Score: 0.014
-
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021 08 10; 39(23):2605-2616.
Score: 0.014
-
The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma. 2021 06; 62(6):1361-1369.
Score: 0.014
-
ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy. Am J Respir Crit Care Med. 2020 10 15; 202(8):1184-1187.
Score: 0.014
-
Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020 03 24; 4(6):1038-1050.
Score: 0.013
-
Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica. 2020 07; 105(7):1907-1913.
Score: 0.013
-
Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. Am J Clin Oncol. 2019 10; 42(10):789-796.
Score: 0.013
-
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell. 2019 07 25; 178(3):699-713.e19.
Score: 0.012
-
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer J. 2019 05 16; 9(6):48.
Score: 0.012
-
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657.
Score: 0.012
-
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018 10 01; 36(28):2845-2853.
Score: 0.012
-
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. Br J Haematol. 2019 04; 185(2):334-338.
Score: 0.012
-
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018 08; 182(3):404-411.
Score: 0.011
-
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e103-e108.
Score: 0.011
-
Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Am J Surg Pathol. 2017 Oct; 41(10):1309-1321.
Score: 0.011
-
Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017 12; 30(12):1688-1697.
Score: 0.011
-
Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017 06; 39(6):1095-1100.
Score: 0.011
-
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum ?2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br J Haematol. 2016 Oct; 175(2):290-299.
Score: 0.010
-
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. 2016 Oct 15; 122(20):3145-3151.
Score: 0.010
-
A clinician's guide to double hit lymphomas. Br J Haematol. 2015 Mar; 168(6):784-95.
Score: 0.009
-
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014 Aug; 15(9):1019-26.
Score: 0.009
-
Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec; 54(12):2631-8.
Score: 0.008